Pharmaceuticals, Biotechnology and Life Sciences
First pharmaceutical cannabis factory was open in the USA on Tuesday, as Ultra Health, New Mexico’s first cannabis company with a nationwide presence, and Panaxia Pharmaceuticals Industries Ltd, an Israeli pharmaceutical company specializing in pharmaceutical cannabis R&D and manufacturing launched their facility in Bernalillo, New Mexico.
Board of Directors has appointed its former executive vice preisdent Claus Bo Svendsen, as Chief Executive Officer, as it plans to pursue important objectives related to the the Settlement and License Agreement with Biogen.
Eli Lilly has completed acquisition of CoLucid Pharmaceuticals at a price of $46.50 per share through a second-step merger.
Novo Nordisk’s executive vice president, head of North America Operations and president of Novo Nordisk Inc. Jakob Riis has resigned from the company, and will be replaced by senior vice president for Market Access, Doug Langa.
According to Deloitte’s 2017 Global Health Care Sector Outlook the challenges of providing and funding healthcare around the world are likely to continue this year due to the rising demands and associated spending of the aging population, the growing prevalence of chronic diseases and comorbidities, the development of costly clinical innovations, increasing patient expectations, and continued economic turbulence.
ASIT biotech, a Belgian clinical-stage biopharmaceutical company could soon market its gp-ASIT+ grass pollen product, as it showed positive results in Phase III clinical trial in grass pollen rhinitis.
US Food and Drug Administration (FDA) has approved AstraZeneca’s once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.
Johnson & Johnson has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott for $4.325 billion
Matinas BioPharma Holdings has been approved for listing on the New York stock exchange, and will be trading under the symbol “MTNB” starting from March 2, 2017.
Exelixis and Bristol-Myers Squibb have entered into a clinical development collaboration to evaluate Cabometyx (cabozantinib), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab).